The group representing drugmakers is lobbying the provincial government.
Innovative Medicines Canada (Médicaments novateurs Canada) was registered in-house this past week by its president Bettina Hamelin. Stefani Vukmanovic, a consultant with Rubicon Strategy Inc., also registered to lobby on behalf of the group.
According to the mandatory filing with the Office of the Integrity Commissioner, the primary focus of the lobbying efforts is to discuss any provincial and federal legislation, initiatives, policy and/or regulations that may impact Ontario such as pricing board, pharmacare, drugs for rare diseases, accelerated access, bulk purchasing, and trade/tariff impact to the pharmaceutical industry. The group also wants to discuss any new pieces of legislation, regulation or policy initiatives that impact the client’s member companies and/or patient access to innovative medications or vaccines. The goal is to ensure timely access to innovative medicines that improve health outcomes for Ontarians, while also driving positive economic growth in Ontario.